Novo Nordisk to cut U.S. GLP-1 drug prices by up to 50% in 2027
Novo Nordisk said U.S. list prices for Wegovy, Ozempic, and Rybelsus will be cut by up to 50% to $675 per month starting Jan. 1, 2027, targeting insured patients with high-deductible plans or co-insurance and potentially lowering out-of-pocket costs; Medicare prices will also drop to $274 per month under the Inflation Reduction Act, aiming to boost access and competition in the GLP-1 market.